Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
13F holders, Q2 2021
Institutional positions in Verona Pharma plc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- 0 vs. Q1 2021
- Shares held
- 36.7M
- +168.7K (+0.5%) vs. Q1 2021
- Total value
- $239.9M
- −$65.2M (−21.4%) vs. Q1 2021
- New holders
- 6
- 5 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $359.0K |
| Q3 2025 | 243 | $8.57B |
| Q2 2025 | 292 | $7.18B |
| Q1 2025 | 258 | $4.58B |
| Q4 2024 | 191 | $3.19B |
| Q3 2024 | 150 | $1.95B |
| Q2 2024 | 125 | $957.0M |
| Q1 2024 | 113 | $1.08B |
| Q4 2023 | 117 | $1.35B |
| Q3 2023 | 102 | $1.07B |
| Q2 2023 | 105 | $1.33B |
| Q1 2023 | 95 | $1.21B |
| Q4 2022 | 88 | $1.31B |
| Q3 2022 | 68 | $529.0M |
| Q2 2022 | 40 | $145.9M |
| Q1 2022 | 39 | $181.7M |
| Q4 2021 | 42 | $248.0M |
| Q3 2021 | 40 | $202.7M |
| Q2 2021 | 37 | $239.9M |
| Q1 2021 | 37 | $305.1M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Verona Pharma plc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 5,694,841 | $37.2M | 0.38% | 00.0% | Unchanged |
| NEA Management Company, LLC | 5,108,563 | $33.4M | 0.44% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 5,100,000 | $33.4M | 0.54% | 00.0% | Unchanged |
| Wellington Management Group LLP | 3,911,840 | $25.6M | 0.00% | +113,699+3.0% | Added |
| Vivo Capital, LLC | 3,048,507 | $19.9M | 0.86% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 2,888,889 | $18.9M | 0.25% | 00.0% | Unchanged |
| Abingworth LLP | 2,457,499 | $16.0M | 4.95% | 00.0% | Unchanged |
| Aisling Capital Management LP | 1,332,485 | $8.71M | 1.40% | 00.0% | Unchanged |
| Foresite Capital Management III, LLC | 1,111,112 | $7.27M | 7.70% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,111,112 | $7.27M | 0.96% | 00.0% | Unchanged |
| Ghost Tree Capital, LLC | 1,000,000 | $6.54M | 2.05% | +60,957+6.5% | Added |
| Polar Capital Holdings Plc | 900,000 | $5.89M | 0.03% | −100,000−10.0% | Reduced |
| Sphera Funds Management Ltd. | 801,256 | $5.24M | 0.50% | 00.0% | Unchanged |
| Novo Holdings A/S | 761,205 | $4.98M | 0.22% | −77,155−9.2% | Reduced |
| Tekla Capital Management LLC | 751,905 | $4.92M | 0.16% | 00.0% | Unchanged |
| BlackRock Inc. | 249,941 | $1.64M | 0.00% | +249,941 | New |
| venBio Partners LLC | 161,897 | $1.06M | 0.12% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 83,944 | $549.0K | 0.23% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 58,200 | $381.0K | 0.00% | +1,700+3.0% | Added |
| D.A. Davidson & Co. | 41,900 | $274.0K | 0.00% | 00.0% | Unchanged |
| IHT Wealth Management, LLC | 18,560 | $121.0K | 0.01% | −130−0.7% | Reduced |
| Wedbush Securities Inc | 18,035 | $118.0K | 0.01% | −3,965−18.0% | Reduced |
| Forefront Analytics, LLC | 15,506 | $104.0K | 0.04% | +1,404+10.0% | Added |
| HSBC Holdings PLC | 15,041 | $101.0K | 0.00% | 00.0% | Unchanged |
| Quantitative Systematic Strategies LLC | 14,034 | $92.0K | 0.03% | −15,136−51.9% | Reduced |
| Rathbone Brothers plc | 11,959 | $78.0K | 0.00% | 00.0% | Unchanged |
| Chicago Partners Investment Group LLC | 10,006 | $58.0K | 0.00% | +10,006 | New |
| Brewin Dolphin Ltd | 4,415 | $28.9K | 0.00% | 00.0% | Unchanged |
| US Bancorp | 3,840 | $25.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3,674 | $24.0K | 0.00% | +2,174+144.9% | Added |
| Bank of America Corp | 3,355 | $22.0K | 0.00% | +3,355 | New |
| Parallel Advisors, LLC | 2,000 | $13.0K | 0.00% | +2,000 | New |
| Endurance Wealth Management, Inc. | 2,000 | $12.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,365 | $9.00K | 0.00% | +1,365 | New |
| Fifth Third Bancorp | 1,000 | $7.00K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 10 | $0 | 0.00% | −100−90.9% | Reduced |
| Deutsche Bank AG | 58 | $0 | 0.00% | +58 | New |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −36,638−100.0% | Sold out |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −18,337−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,035−100.0% | Sold out |
| Personal Cfo Solutions, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,407−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −35−100.0% | Sold out |